These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

303 related items for PubMed ID: 14610641

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study.
    Delmas PD, Adami S, Strugala C, Stakkestad JA, Reginster JY, Felsenberg D, Christiansen C, Civitelli R, Drezner MK, Recker RR, Bolognese M, Hughes C, Masanauskaite D, Ward P, Sambrook P, Reid DM.
    Arthritis Rheum; 2006 Jun; 54(6):1838-46. PubMed ID: 16729277
    [Abstract] [Full Text] [Related]

  • 7. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study.
    Miller PD, McClung MR, Macovei L, Stakkestad JA, Luckey M, Bonvoisin B, Reginster JY, Recker RR, Hughes C, Lewiecki EM, Felsenberg D, Delmas PD, Kendler DL, Bolognese MA, Mairon N, Cooper C.
    J Bone Miner Res; 2005 Aug; 20(8):1315-22. PubMed ID: 16007327
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Oral and intravenous ibandronate in the management of postmenopausal osteoporosis: a comprehensive review.
    Reginster JY.
    Curr Pharm Des; 2005 Aug; 11(28):3711-28. PubMed ID: 16305506
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis.
    Recker R, Stakkestad JA, Chesnut CH, Christiansen C, Skag A, Hoiseth A, Ettinger M, Mahoney P, Schimmer RC, Delmas PD.
    Bone; 2004 May; 34(5):890-9. PubMed ID: 15121021
    [Abstract] [Full Text] [Related]

  • 13. Effect of daily and intermittent use of ibandronate on bone mass and bone turnover in postmenopausal osteoporosis: a review of three phase II studies.
    Schimmer RC, Bauss F.
    Clin Ther; 2003 Jan; 25(1):19-34. PubMed ID: 12637110
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Update on monthly oral bisphosphonate therapy for the treatment of osteoporosis: focus on ibandronate 150 mg and risedronate 150 mg.
    Epstein S, Jeglitsch M, McCloskey E.
    Curr Med Res Opin; 2009 Dec; 25(12):2951-60. PubMed ID: 19835464
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Alendronate treatment of established primary osteoporosis in men: 3-year results of a prospective, comparative, two-arm study.
    Ringe JD, Dorst A, Faber H, Ibach K.
    Rheumatol Int; 2004 Mar; 24(2):110-3. PubMed ID: 13680141
    [Abstract] [Full Text] [Related]

  • 19. Optimizing the management of postmenopausal osteoporosis with bisphosphonates: the emerging role of intermittent therapy.
    Miller PD.
    Clin Ther; 2005 Apr; 27(4):361-76. PubMed ID: 15922811
    [Abstract] [Full Text] [Related]

  • 20. Changes in bone mineral density after kidney transplantation: 2-year assessment of a French cohort.
    Segaud N, Legroux I, Hazzan M, Noel C, Cortet B.
    Osteoporos Int; 2018 May; 29(5):1165-1175. PubMed ID: 29500526
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.